Boston, Mass.-based investment company Omega Fund Management LLC raised $438 million in capital commitments via its sixth venture capital fund named Omega Fund VI LP.
The company said it will continue its strategy of creating and investing in life sciences companies targeting urgent medical needs.
Omega said investments from Fund VI will use various investment approaches, including company founding and creation, early venture rounds, late-stage public investing and direct secondary transactions.
Omega Fund is an investment company that targets biotechnology and medical device businesses based in North America and Western Europe. According to the company's press release dated Dec. 11, Omega Funds has raised more than $1 billion to invest in entrepreneurs developing products across different therapeutic areas including oncology, immunology, rare diseases and precision medicine since 2004.